First-of-Its-Kind Human Tissue Study Finds Link Between NAD Decline and Alcohol-Related Liver Disease (ArLD)

LOS ANGELES–(BUSINESS WIRE)—- $CDXC #ArLD–ChromaDex Corp. (NASDAQ: CDXC), the global scientific authority on nicotinamide adenine dinucleotide (NAD) and nicotinamide riboside (NR) science, announced today the publication of a study evaluating the NAD metabolome in human liver samples from people with liver diseases including alcohol-related liver disease (ArLD). The study, published in Hepatology Communications, was conducted by a collaborative team from the University of Iowa and University of Birmingham